Biosimilars: To Infinity and Beyond - On Demand
Recorded On: 11/14/2023
-
Register
- Prices available after logging in
What is the future of biosimilars in the home and alternate site? There are numerous options now available and even now interchangeable options. We will take a look at various concepts related to biosimilars including transition from the parent product to a biosimilar, determining what is interchangeable, and more.
Learning Objectives:
- Review the legislative impact for pharmacies as it relates to interchangeability of approved molecules in clinical practice.
- Review current requirements for FDA approval of biosimilars and interchangeability requirements for biosimilars.
- Describe potential processes to overcome barriers to biosimilar adoption (prescribing, financial, operational).
Jonathan Ogurchak, PharmD, CSP
Co-Founder & CEO
STACK
Jonathan Ogurchak is the Founder & CEO of STACK, a compliance management software designed to simplify the “outside of the dispense” complexities associated with running successful pharmacy organizations. He is also Managing Partner of Rhythm Group, consulting and technology solutions organization, and is a Certified Consultant with Accreditation Commission for Health Care (ACHC). Jonathan has designed programs and services for both Accredo and PANTHERx Specialty Pharmacy focusing on implementing innovative uses for technology, including high-touch pharmacist-driven programs focused on dosing efficiency, clinical monitoring of patient outcomes, and integrated patient engagement. Jonathan is on faculty for the Master of Pharmacy Business Administration (MPBA) program through the University of Pittsburgh, leading the Specialty Pharmacy Management curriculum. He currently serves on the editorial board for Specialty Pharmacy Times, holds CSP Certification through the Specialty Pharmacy Certification Board, and serves as an Educational Consultant for the National Association of Specialty Pharmacy (NASP).
No Disclosures to Report